

Dr Nady Braidy

Citizenship: Australian

Date of Birth: 20th January 1986

Postal Address: P.O. Box 538, Riverwood, Sydney, NSW, Australia, 2210

Phone (H): 02 9533 4140 **Phone (M):** +61431 234 027 **Email:** n.braidy@unsw.edu.au

Employment History

January 2017 – December 2020

ARC Discovery Early Career Researcher Award, Lecturer, Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia, 2052.

January 2013 – December 2016

NHMRC Early Career Postdoctoral Research Fellow, Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia, 2052.

January 2012 - December 2012

Alzheimer's Australia Viertel Foundation Postdoctoral Research Fellow, Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia, 2052.

Academic Qualifications

2008-2011 **PhD student,** University of New South Wales, Sydney, NSW 2052.

2008-2010 **Graduate Certificate in Research Management** (with Distinction)

2005-2010 **Diploma Innovation Management** (with Distinction)

2008-2009 **Masters in Pharmacy,** University of Sydney, Sydney, NSW, 2000

2004-2007 **Bachelor of Medical Science (Class I Honours in Pharmacology and Physiology)** (with Distinction) University of New South Wales, Sydney, NSW 2052

Grants

2017-2020: CID National Health and Medical Research Committee Project Grant (\$593,000)

2017-2019: CIA Australian Research Council Discovery Early Career Researcher Award (\$372,000)

2016: CIC UNSW Goldstar award (\$40,000)

2015-2017: CIA Chilean Postdoctoral Prize (\$180,000)

2013-2016: CIA National Health and Medical Research Council Early Career Postdoctoral Research Fellowship (\$299,000)

2013: CIA UNSW Brain Sciences Seed Grant (\$4,000)

2012-2013: CIA Alzheimer's Australia Viertel Foundation Postdoctoral Research Fellowship (\$180,000)

2012: CIA NSW Faculty of Medicine Research Grant (\$20,000)

Special Achievements and Awards

2014 The Science and Industry Endowment Fund – Australian Academy of Science Fellowships to the 64th Lindau Nobel Laureate Meetings

2012 Dean's Rising Star Award, Faculty of Medicine, UNSW.

2012 International College of Geriatric Psychoneuropharmacology Junior Investigator of the Year, Seville, Spain

2012 American Alzheimer's Association Travel Fellowship to attend the 2012 International Conference on Alzheimer's Disease, Vancouver, Canada

2009 Dean's list, Faculty of Medicine UNSW.

Scientific Contribution

- Utilising CHeBA biospecimens for understanding the brain and the ageing process, my current work is committed to discovering the fundamental causes and possible treatments for age-related neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases, as well as on genetic and metabolic changes that take place as organisms grow old. Working individually and collaboratively across labs and disciplines, I am continuing to uncover novel insights that expand knowledge and promise to enhance quality of life for an ageing population.
- An international collaborative project on developing and validating the Octodon degu as a novel 'natural' animal model for Alzheimer's disease using a combined metallomics, proteomics, lipidomics and metabolomics approach (with Prof Nivaldo Inestrosa, Pontifical Catholic University of Chile, Santiago, Chile) is in progress
- I am the first to show that NAD⁺ levels decline with ageing and enzymes involved in NAD⁺ synthesis are dysregulated during the pace of ageing. Recent research elucidating the molecular mechanism of SIRT1 activation by polyphenols (under review at Nature Biotechnology), and identified a mutation in humans in SIRT1 in dementia patients (under review in Nature).
- During my PhD, I identified the mechanism of quinolinic acid toxicity in primary human astrocytes and neurons. I showed that naturally occurring phytochemicals can protect against excitotoxicity in human brain cells.
- I identified resveratrol as an activator of the NAD⁺ synthetic enzyme, NMNAT1 (Patent) that is producing positive results in clinical trials.

Teaching

Lectures:

Since 2008: Lectures for several undergraduate pharmacology courses in semester 1 and semester 2, SOMS, UNSW. Courses include: PHAR2011; PHAR2211, PHAR3101, PHAR3102; PHAR3202; PHAR3251, PHAR3306.

Laboratory based Teachings:

Currently supervising 2 Honours Students. I have previously supervised 8 Honours students, 2 Masters students and 1 PhD student.

Selected Oral Conference Presentations

2015 NAD⁺ Brain Summit, Springfield Wellness Centre, Natchez, Mississippi, USA. Title: "NAD⁺ as a therapeutic strategy in neurodegenerative diseases" [Invited Speaker]

2013 The 13th Annual International College of Geriatric Psychoneuropharmacology Meeting 2013; Pittsburg, USA. Title: "*In vitro and In vivo models for investigating the pathogenesis of Psychiatric disorders*" [Invited Speaker]

2012 The 12th Annual International College of Geriatric Psychoneuropharmacology Meeting 2012; Seville, Spain. Title: "*Oxidative Stress in Alzheimer's Disease and Ageing: Revisiting the Ancient Phenomenon*" [Invited Speaker].

2011 Australian Neuroscience Conference 2011; Auckland, New Zealand. Title: "*Changes in Kynurenine Pathway Metabolism in the brain of aged female Wistar rats.*"

2010 Australian Neuroscience Conference 2010; Sydney, Australia. Title: "*Age related changes in NAD⁺ metabolism in the brain of aged female Wistar rats.*"

2010 The 8th international conference on toxic cyanobacteria 2010; Istanbul, Turkey. Title: "Excitotoxic potential of the cyanotoxin β-methyl-amino-L-alanine (BMAA) in primary human neurons".

2010 DANDIS Dementia Aging and Neurodegenerative Disease Group Conference 2010; Canberra, Australia. Title: “NAD⁺: A regulator of brain aging.” St. Vincents and Mater Health Sydney Seminar 2009; Sydney, Australia.

Patent / Intellectual Property

2009 (WO/2009/108999) Pharmaceutical Formulations of Resveratrol and Methods of Use Thereof for Treating Cell Disorders. International Application No.: PCT/AU2009/000255 Publication Date: 11.09.2009

Publication List

Journal Articles Published (since 2008) (h index 21 Scopus February 2017)

2017

1. Daglia M, Di Lorenzo A, Nabavi SF, Sureda A, Khanjani S, Moghaddam AH, **Braidy N**, Nabavi SM (2017). Improvement of antioxidant defences and mood status by oral GABA tea administration in a mouse model of post-stroke depression. *Nutrients* [In press, accepted 03/2017] [Q1; IF: 3.759; Cited 0]
2. D' Mello F, **Braidy N**, Marçal H, Guillemin G, Nabavi SM, Neilan BA (2017). Mechanisms and Effects Posed by Neurotoxic Products of Cyanobacteria/ Microbial Eukaryotes/dinoflagellates in Algae Blooms: A review. *Neurotox Res* [In press, accepted 03/2017] [Q1; IF: 3.151; Cited 0]
3. **Braidy N**, Poljak A, Marjo C, Rutledge H, Rich A, Jugder B-E, Jayasena T, Inestrosa N, Sachdev P (2017). Identification of cerebral metal ion imbalance in the brain of ageing Octodon degus. *Front Aging Neurosci.* [In press, accepted 02/2017] [Q1; IF: 4.5; Cited 0]
4. Wong M, **Braidy N**, Poljak A, Pickford R, Thambisetty M, Sachdev P (2017). Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers. *Alzheimer's and Dementia* [In press, accepted 01/2017] [Q1; IF: 11.219; Cited 0]
5. **Braidy N**, Grant R (2017). Invited Perspective: Kynurenine pathway metabolism and neuroinflammatory. *Neural Regeneration Research.* [In press, accepted 01/2017] [Q1; IF: 0.968; Cited 0]
6. **Braidy N**, Behzad S, Habtemariam S, Ahmed T, Daglia M, Nabavi SM, Sobarzo-Sanchez E, Nabavi SF (2017). Neuroprotective effects of citrus fruit-derived flavonoids, nobiletin and tangeretin: a mini review. *CNS and Neurodegenerative Diseases: Drug Targets* [In press, accepted 02/2017] [Q1; IF: 3.155; Cited 0]
7. Srinivasan V, **Braidy N**, Xu Y-H, Xie P, Kancherla K, Chandramohan S, Chan EKW, Chan DKY (2017) Association of Genetic Polymorphisms of Claudin-1 with Small Vessel Vascular Dementia. *Clinical and Experimental Pharmacology and Physiology* [In press, accepted 02/2017] [Q1; IF: 2.155; Cited 0]
8. Shariflou S, Georgevsky D, Mansour H, Rezaeian M, Hosseini N, Gani F, Gupta V, **Braidy N**, Golzan SM (2017). Diagnostic and prognostic potential of retinal biomarkers in early on-set Alzheimer's disease. *Current Alzheimer Research* [In press, accepted 02/2017] [Q1; IF: 3.796; Cited 0]
9. **Braidy N**, Jugder B-E, Poljak A, Jayasena T, Sachdev P, Grant R (2017). Molecular targets of Tannic Acid in Alzheimer's disease. *Current Alzheimer Research.* [In press, accepted 02/2017] [Q1; IF: 3.796; Cited 0]
10. Rahimifard M, Maqbool F, Moeini-Nodeh S, Niaz K, Abdollahi M, **Braidy N**, Nabavi SM, Nabavi SF (2017). Targeting the TLR4 signaling pathway by polyphenol: A novel therapeutic strategy for neuroinflammation. *Ageing Res Rev.* [In press, accepted 02/2017] [Q1; IF: 7.628; Cited 0]

2016

11. Gokoolparsadh A, Fang Z, **Braidy N**, Voineagu I (2016). Topoisomerase I inhibition leads to length-dependent gene expression changes in human primary astrocytes. *Genomics Data* [In press, accepted 12/2016] [Q1; IF: n/a; Cited 0]
12. Grant R, Berg J, **Braidy N** (2016). Promoting NAD⁺ metabolism: A new target for treating degenerative disease. *Australian College of Nutritional and Environmental Medicine Journal* [In press, accepted 12/2016] [IF: n/a; Cited 0]
13. Wong M, **Braidy N**, Poljak A, Sachdev P (2016). The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease. *Current Opinion in Psychiatry* [In press, accepted 12/2016] [Q1; IF: 3.551; Cited 0]
14. Gokoolparsadh A, Fang Z, **Braidy N**, Lin P, Pardy CJ, Eapen V, Clarke R, Voineagu I (2016). Transcriptional response to mitochondrial protease IMMP2L knockdown in human primary astrocytes. *Biochemical and Biophysical Research Communications* [In press, accepted 12/2016] [Q1; IF: 2.371; Cited 0]
15. Ajami M, Pazoki-Toroudi H, Amani H, Nabavi SF, **Braidy N**, Vacca RA, Atanasov AG, Mocan A, Nabavi SM (2016). Targeting SIRT1 signaling by polyphenols: a 'lock and key' strategy for the treatment of neurodegeneration *Neuroscience and Biobehavioural Reviews* [In press, accepted 11/2016] [Q1; IF: 8.580; Cited 0]
16. Vacca RA, Valenti D, Caccamese S, Daglia M, **Braidy N**, Nabavi SM (2016). Plant polyphenols as natural drugs for the management of Down Syndrome and related disorders. *Neuroscience and Biobehavioural Reviews* [In press, accepted 10/2016] [Q1; IF: 8.580; Cited 0]
17. Suganthi N, Devi KP, Nabavi SF, **Braidy N**, Nabavi SM (2016). Bioactive effects of quercetin in the central nervous system: Focusing on the mechanisms of action. *Biomedicine and Pharmacotherapy* [In press, accepted 10/2016] [Q1; IF: 2.326; Cited 0]
18. Jugder B-E, Ertan H, Wong YK, **Braidy N**, Manfield M, Marquis CP, Lee M (2016). Genomic, Transcriptomic and Proteomic Analyses of *Dehalobacter UNSWDHB* in Response to Trichloromethane. *Environmental Microbiol Rep* [In press, accepted 07/2016] [Q1; IF: 3.5; Cited 0]
19. Amani H, Pazoki-Toroudi H, Ajami M, Nabavi SF, **Braidy N**, Devi KP, Nabavi SM (2016). Targeting mTOR signaling by polyphenols: a new therapeutic target for ageing. *Ageing Res Rev.* [In press, accepted 06/2016] [Q1; IF: 7.628; Cited 10]
20. Jugder B-E, Welch J, **Braidy N**, Marquis CP (2016). Molecular characterisation of a soluble hydrogenase promoter (PSH) from *Cupriavidus necator* H16 using a reporter gene, gfp (green fluorescent protein). *Peer J* [In press, accepted 06/2016] [Q1; IF: 2.100; Cited 0]
21. **Braidy N**, Essa MM, Poljak A, Subash S, Al-Adawi S, Manivasagam T, Thenmozhi AJ, Ooi L, Sachdev P, Guillemin GJ (2016). Consumption of pomegranates reduces amyloid-beta and improves synaptic function in a transgenic mice model of Alzheimer's disease. *Oncotarget* [In press, accepted 05/2016] [Q1; IF: 6.391; Cited 0]
22. Chan D, **Braidy N**, Xu YH, Chataway T, Guo F, Guillemin GJ, Teo C, Gai WP (2016). Interference of α -synuclein uptake by monomeric β -Amyloid₁₋₄₀ and potential core acting site of the interference. *Neurotox Res* [In press, accepted 05/2016] [Q1; IF: 3.151; Cited 0]
23. **Braidy N**, Rossez H, Lim CK, Jugder B-E, Brew BJ, Guillemin G (2016). Characterisation of the kynurenine pathway in CD8⁺ human primary monocyte derived dendritic cells. *Neurotox Res* [In press, accepted 05/2016] [Q1; IF: 3.151; Cited 0]
24. D' Mello F, **Braidy N**, Marcal H, Guillemin G, Rossi F, Chinian M, Laurent D, Teo C, Neilan B (2016). Cytotoxic effects of environmental toxins of human glial cells. *Neurotox Res* [In press, accepted 05/2016] [Q1; IF: 3.151; Cited 0]
25. Tan V, Le JM, Lovejoy D, **Braidy N**, Brew BJ, Guillemin, GJ (2016). Role of quinolinic acid in the neuropathogenesis of ALS. *Neuropharmacology* [In press, accepted 05/2016] [Q1; IF: 5.106; Cited 0]
26. Devi KP, Malar DS, **Braidy N**, Nabavi SM, Nabavi SF (2016). A mini review on the chemistry and neuroprotective effects of silymarin. *CNS Drug Targ* [In press, accepted 03/2016] [Q1; IF: 2.9; Cited 0]

27. Tejada S, Setzer W, Daglia M, Nabavi SF, Sureda A, **Braidy N**, Gortzi O, Nabavi SM (2016). Neuroprotective effects of Ellagitannins: a brief review. *Curr Drug Targ* [In press, accepted 03/2016] [Q1; IF: 2.9; Cited 0]
28. Ahmad T, Raza SH, Maryam A, Setzer W, **Braidy N**, Nabavi SF, de Oliveira MR, Nabavi SM (2016). Ginsenoside RB₁ as neuroprotective agent: a review. *Brain Res Bull*. [In press, accepted 03/2016] [Q1; IF: 2.718; Cited 0]
29. Jayasena T, Poljak A, **Braidy N**, Zhong L, Rowlands B, Muenchhoff J, Grant R, Smythe G, Teo C, Raftery M, Sachdev P (2016). Application of Targeted Mass Spectrometry for the quantification of sirtuins in the central nervous system. *Sci Rep*. [In press, accepted 03/2016] [Q1; IF: 5.078; Cited 0]
30. Ahmad T, Javed S, Javed S, Tariq A, Samec D, Tejada S, Nabavi SF, **Braidy N**, Nabavi SM (2016). Resveratrol and Alzheimer's disease: a mechanistic review. *Mol Neurobiol*. [In press, accepted 03/2016] [Q1; IF: 5.286; Cited 0]
31. Srinivasan V, **Braidy N**, Chan EKW, Xu YH, Chan DKY (2016). Genetic and Environmental Factors in Vascular Dementia: an update of blood brain barrier dysfunction. *Clin Exp Pharm Phys*. [In press, accepted 01/2016] Q1; IF: 2.372; Cited 0]
32. de Oliveira MR, Nabavi SM, **Braidy N**, Setzer WN, Touqeer A, Nabavi SF (2016). Quercetin and the mitochondria: a mechanistic approach. *Biotech Adv*. [In press, accepted 01/2016] Q1; IF: 9.785; Cited 0]
33. Lim E, Gomez F, Estrada C, **Braidy N**, Costa C, Cosat S, Fernandez-Villalba E, Herrero MT, Guillemin GJ (2016). Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease: Is there a link? *Prog Neurobiol* [In press, accepted 01/2016]. [Q1; IF: 9.992; Cited 0]
34. Nabavi SF, **Braidy N**, Orhan IE, Badiie A, Daglia M, Nabavi SM (2016). *Rhodiola rosea* L. and Alzheimer's disease: from farm to pharmacy. *Phytother Res*. [In press, accepted 12/2015] [Q1; IF: 2.66; Cited 0]
35. Ahmed T, Setzer W, Nabavi SF, Orhan IE, **Braidy N**, Sobarzo-Sanchez E, Nabavi SM (2016). Insights into effects of ellagic acid on the nervous system: a mini review. *Curr Pharm Des*. [In press, accepted 09/2015] [Q1; IF: 3.452; Cited 0]
36. **Braidy N**, Jugder B-E, Poljak A, Jayasena T, Mansour H, Nabavi SM, Sachdev P, Grant R (2016). Is resveratrol likely to be an effective agent in therapeutic intervention for Alzheimer's disease? *Curr Topics Med Chem*. [In press, accepted 06/2015] [Q1; IF: 3.453; Cited 0]
37. Nabavi SF, **Braidy N**, Habtemariam S, Sureda A, Manavi A, Nabavi SM (2016). Neuroprotective effects of Fisetin in Alzheimer's and Parkinson's diseases: from chemistry to medicine. *Curr Topics Med Chem*. [In press, accepted 06/2015] [Q1; IF: 3.453; Cited 0]
38. Nabavi SF, Tejada S, Setzer W, Gortzi O, Sureda A, **Braidy N**, Daglia M, Manayi A, Nabavi SM (2016). Chlorogenic acid and mental diseases: from chemistry to medicine. *Curr Neuropharm*. [In press, accepted 09/2015] [Q1; IF: 3.049; Cited 0]

2015

39. Nabavi SF, Daglia M, **Braidy N**, Nabavi SM (2015). Natural products, micronutrients, and nutraceuticals for the treatment of depression: A short review. *Nutr Neurosci*. [In press, accepted 09/2015] [Q1; IF: 1.765; Cited 0]
40. Nabavi SF, **Braidy N**, Gortzi O, Sobarzo-Sanchez E, Daglia M, Skalicka-Wozniak K., Nabavi SM (2015). Luteolin as an anti-inflammatory and neuroprotective agent: a brief review. *Brain Res Bull*. 119(Pt A):1-11 [Q1; IF: 2.718; Cited 0]
41. Nabavi SF, **Braidy N**, Habtemariam S, Orhan IE, Daglia M, Manayi A, Gortzi O, Nabavi SM (2015). Neuroprotective effects of chrysin: from chemistry to medicine. *Neurochem Int*. 90:224-31 [Q1; IF: 3.092; Cited 0]
42. Nabavi SM, Habtemariam S, Daglia M, **Braidy N**, Loizzo MR, Tundis R, Nabavi SF (2015). Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: a Review of Current Literature. *Curr Topics Med Chem*. 15:2222-32. [Q1; IF: 3.453; Cited 0]
43. **Braidy N**, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, Smythe G, Sachdev P, Guillemin GJ (2015). Differential expression of sirtuins in the ageing rat brain. *Front Cell Neurosci*. 9:167 [Q1; IF: 4.5; Cited 0]

44. **Braidy N**, Zarka M, Welch J, Bridge W (2015). Therapeutic approaches for modulating Glutathione levels as a pharmacological strategy in Alzheimer's disease. *Curr Alzheimer Res.* 12: 1-16.[Q1; IF: 3.796; Cited 0]
45. Chui AS, **Braidy N**, Marcal H, Welch JH, Gehringer MM, Neilan BA (2015). Global cellular responses to β -methyl-amino-L-alanine (BMAA) by olfactory ensheathing glial cells (OEC). *Toxicol* 99: 136-145. [Q1; IF: 2.581; Cited 0]
46. Subash S, **Braidy N**, Essa MM, Al-Buraiki Z, Vaishnav R, Al-Adawi S, Al-Asmi A, Guillemin GJ (2015). Long term (15 Months) dietary supplementation with pomegranates from Oman attenuated cognitive and behavioural deficits in a transgenic mice model of Alzheimer's disease. *Nutrition.* 31: 223-229. [Q2; IF: 2.635; Cited 0]
47. Bastias-Candia S, **Braidy N**, Zolezzi JM, Inestrosa NC (2015). Teneurins in Alzheimer's disease: A suggestive role for a unique family of proteins. *Med Hypotheses.* 84: 402-7[Q2; IF: 1.152; Cited 0]
48. **Braidy N**, Poljak A, Jayasena T, Mansour H, Inestrosa NC, Sachdev P (2015). Accelerating Alzheimer's research through 'natural' animal models. *Curr Opin Psychiatry* 28: 155-164. [Q1; IF: 3.551; Cited 0]
49. Jayasena T, Poljak A, **Braidy N**, Smythe G, Raftery M, Hill M, Brodaty H, Trollor J, Kochan N, Sachdev P (2015). Upregulation of glycolysis pathway and increased cytotoxicity in glial cells treated with Alzheimer's disease plasma. *PLoS One* 10: e0116092 [Q1; IF: 3.530; Cited 0]
50. Sheipouri D, Grant R, Bustamante S, Lovejoy D, Guillemin GJ, **Braidy N** (2015). Characterisation of the kynurenine pathway in skin-derived fibroblasts and keratinocytes. *J Cell Biochem.* 116: 903-922 [Q1; IF: 3.368; Cited 0]

2014

51. Godoy JA, Ordenes D, Arrazola MS, Silva-Alvarez C, **Braidy N**, Inestrosa NC (2014). Wnt-5a modulates mitochondrial fission-fusion in rat Hippocampal Neurons. *J Biol Chem.* 289: 36179-93.[Q1; IF: 4.6; Cited 0]
52. Rios JA, Cisternas P, Tapia-Rojas C, Rivera D, **Braidy N**, Carvajal FJ, Ardiles AO, Bozinovic F, Palacios AO, Sachdev P, Inestrosa NC, (2014). Age-related neurodegeneration in the brain of Octodon degus: A 'natural' model for Alzheimer's disease. *Brain Pathol.* [In press, accepted 10/2014]. [Q1; IF: 4.354; Cited 0]
53. Adams S, Teo C, McDonald K, Zinger A, Bustamante S, Lim CK, Sundaram G, **Braidy N**, Brew BJ, Guillemin GJ (2014). Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology. *PLoS One.* 9: e112945.[Q1; IF: 3.530; Cited 0]
54. Essa MM, **Braidy N**, Bridge W, Subash S, Manivasagam T, Vijayan RK, Al-Adawi S, Guillemin GJ (2014). Review of natural products on Parkinson's Disease pathology. *J Age Res ClinPrac.* 3: 127-136[Q3; IF: n/a; Cited 0]
55. Subash S, Essa MM, Al-Asmi A, Al-Adawi S, Vaishnav R, **Braidy N**, Manivasagam T, Guillemin GJ (2014). Pomegranates from Oman alleviates the brain oxidative damage in a transgenic mouse model of Alzheimer's Disease. *J Trad Complem Med.* 4: 232-238. [Q3; IF: n/a; Cited 1]
56. Subash S, Essa MM, **Braidy N**, Kathyia A-T Z, Vaishnav R, Al-Adawi S, Al-Asmi A, Guillemin GJ (2014). Diet rich in palm fruits improve memory deficit and learning skills and reduces amyloid beta in a transgenic mouse model of Alzheimer's Disease. *J Ayurvedic Integ Med.* [In press, accepted 08/2014]. [Q3; IF: n/a; Cited 0]
57. Al-Adawi S, **Braidy N**, Essa M, Al-Azri F, Hussain S, Al-Sibani N, Al-Khabouri J, Al-Asmi A, Al-Mashani A (2014). Cognitive profiles in patients with multi-infarct Dementia: An Omani study. *Dement Geriatr Cogn Disord Extra.* 4: 271-282.[Q3; IF: n/a; Cited 0]
58. **Braidy N**, Subash S, Essa MM, Al-Buraiki Z, Vaishnav R, Al-Adawi S, Al-Asmi A, Al-Senawi AAR, Alobaidy H, Lakhtakia R, Guillemin GJ (2014). Neuroprotective effects of a variety of pomegranate juice extracts (PJE) against the excitotoxin quinolinic acid in human primary neurons. *J Prev Alz Dis.* 1: 84-90[Q3; IF: n/a; Cited 0]
59. Subash S, Essa MM, **Braidy N**, Al-Jabri A, Vaishnav R, Al-Adawi S, Al-Asmi A, Guillemin GJ (2014). Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer's disease. *Nutr Neurosci* [In press, accepted 06/2014]. [Q2; IF: 2.114; Cited 0]

60. **Braidy N**, Brew BJ, Inestrosa NC, Chung R, Sachdev P, Guillemin GJ (2014). Changes in Cathepsin D and Beclin-1 mRNA and Protein Expression by the Excitotoxin Quinolinic Acid in Human Astrocytes and Neurons. *Metab Brain Dis.* 29: 873-883 [Q2; IF: 2.398; Cited 0]
61. Godoy JA, Rios JA, **Braidy N**, Inestrosa NC (2014). Signaling pathway cross talk in Alzheimer's disease. *Cell Commun Signal.* 12: 23 [Q1; IF: 4.672; Cited 4]
62. **Braidy N**, Poljak A, Marjo C, Rutledge H, Rich A, Jayasena T, Inestrosa NC, Sachdev P (2014). Metal and Complementary Molecular Bioimaging in Alzheimer's Disease. *Front Aging Neurosci.* 6: 138[Q1; IF: 4.000; Cited 1]
63. Chan C, Upton C, **Braidy N**, Khalil J, Fang ZM, Xu YH, Chan DKY (2014). Association of leukocyte telomere length with vascular dementia and cancer mortality in an elderly population. *J Am Geriatr Soc.* 62: 1384-1386.[Q1; IF: 4.216; Cited 0]
64. Godoy JA, Zolezzi JM, **Braidy N**, Inestrosa NC (2014). Role of SIRT1 during the ageing process: Relevance to protection of synapses in the brain. *Mol Neurobiol.*50: 744-756. [Q1; IF: 5.286; Cited 3]
65. **Braidy N**, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, Guillemin GJ, Smythe G, Sachdev P (2014). Mapping NAD⁺ Metabolism in the Brain of Ageing Wistar Rats: Potential Targets for Influencing Brain Senescence. *Biogerontol.*15: 177-198. [Q1; IF: 3.01; Cited 4]
66. **Braidy N**, Matin A, Rossi F, Chinain M, Laurent D, Guillemin GJ (2014). Neuroprotective effects of rosmarinic acid on ciguatoxin in primary human neurons. *Neurotox Res.* 25: 226-234. [Q1; IF: 3.151; Cited 0] *
67. **Braidy N**, Gai W-P, Xu YH, Sachdev P, Guillemin GJ, Jiang X-M, Ballard JWO, Horan MP, Fang ZM, Chong BH, Chan DKY (2014). Alpha-Synuclein transmission and mitochondrial toxicity in primary human foetal enteric neurons *in vitro*. *Neurotox Res.* Sep 12. 25: 170-182. [Q1; IF: 3.151; Cited 2]

2013

68. **Braidy N**, Lim CK, Grant R, Brew BJ, Guillemin GJ (2013). Serum Nicotinamide Adenine Dinucleotide Levels Through Disease Course in Multiple Sclerosis. *Brain Res.*1537:267-72. [Q2; IF: 2.828; Cited 0]
69. **Braidy N**, Subash S, Essa MM, Vaishnav R, Al-Adawi S, Al-Asmi A, Al-Senawi H, Alobaidy AAR, Lakhtakia R, Guillemin GJ (2013). Neuroprotective effects of a variety of Pomegranate Juice extracts (PJE) against MPTP-induced cytotoxicity and oxidative stress in human primary neurons. *Oxid Med Cell Longev.*2013: 685909[Q1; IF: 3.350; Cited 4]
70. Tamilselvam K, **Braidy N**, Manivasagam T, Essa MM, Prasad NR, Karthikeyan S, Thenmozhi AJ, Subash S, Guillemin GJ (2013). Neuroprotective effects of hesperidin, a plant flavanone on rotenone induced oxidative stress and apoptosis in a cellular model for Parkinson's Disease. *Oxid Med Cell Longev.*2013: 102741.[Q1; IF: 3.350; Cited 5]
71. **Braidy N**, Gai W-P, Xu YH, Sachdev P, Guillemin GJ, Jiang X-M, Ballard JWO, Horan MP, Fang ZM, Chong BH, Chan DKY (2013). Uptake and Mitochondrial Dysfunction of Alpha-Synuclein in Human Astrocytes, Cortical Neurons, and Fibroblasts. *Transl Neurodegener.* 2: 20. [Q3; IF: n/a; Cited 2]
72. Jayasena T, Poljak A, Smythe G, **Braidy N**, Munch G, Sachdev P (2013). The role of polyphenols in the modulation of sirtuins and pathways involved in Alzheimer's disease. *Ageing Res Rev.* 12: 867-883. [Q1; IF: 7.628; Cited 10]
73. Al-Asmi A, Al-Maniri A, Al-Farsi YM, Burke DT, Al-Asfoor FM, Al-Busaidi I, Al-Breiki MH, Lahiri S, **Braidy N**, Essa MM, Al-Adawi S (2013). Types and Socio-demographic Correlates of Complementary and Alternative Medicine (CAM) Use among People with Epilepsy in Oman. *Epilepsy Behav.*29: 361-366.[Q1; IF: 2.061; Cited 0]
74. Chiu AS, Gehringer MM, **Braidy N**, Guillemin GJ, Welch J, Neilan BA (2013). Demonstrated gliotoxicity of the cyanotoxin, β -methyl-amino-L-alanine (BMAA). *Sci Rep.* 3: 1482. [Q1; IF: 5.078; Cited 3]
75. Sachdev PS, Zhuang L, **Braidy N**, Wen W (2013). Is Alzheimer's a disease of the white matter? *Curr Opin Psychiatry.* 26: 244-251. [Q1; IF: 3.551; Cited 8]
76. Essa MM, **Braidy N**, Waly MI, Al-Farsi YM, Al-Sharbati M, Subash S, Amanat A, Al-Shaffaee MA, Guillemin GJ (2013). Impaired Antioxidant Status and Reduced Energy Metabolism in Autistic Children. *Res Aut Spect Dis.* 7: 557-565. [Q1; IF: 2.378; Cited 3]

77. Essa MM, **Braidy N**, Vijayan KR, Subash S, Guillemin GJ (2013). Excitotoxicity in the Pathogenesis of Autism. *Neurotox Res*. 23: 393-400 [Q1; IF: 3.151; Cited 16]
78. Essa MM, Subash S, **Braidy N**, Lim CK, Guillemin GJ (2013). Role of NAD⁺, Oxidative Stress and Tryptophan Metabolism in Autism Spectrum Disorders. *IJTR* 6: 1-14 (Suppl 1) [Q3; IF: n/a; Cited 0]

2012

79. Adams S, **Braidy N**, Bessede A, Brew BJ, Grant R, Teo C, Guillemin GJ (2012). The kynurenine pathway in brain tumor pathogenesis. *Cancer Res*. 72:5649-57. [Q1; IF: 9.284; Cited 17]
80. Chiu AS, Gehringer MM, **Braidy N**, Guillemin GJ, Welch JH, Neilan BA (2012). Excitotoxic potential of the cyanotoxin β -methyl-amino-L-alanine (BMAA) in primary human neurons. *Toxicol* 60:1159-1165. [Q1; IF: 2.581; Cited 10]
81. Sheipouri D, **Braidy N**, Guillemin GJ (2012). Kynurenine Pathway in Skin Cells: Implications for UV-Induced Skin Damage. *IJTR* 5:15-25 [Q3; IF: n/a; Cited 1]
82. Essa MM, Vijayan KR, Castellano-Gonzalez G, Memon MA, **Braidy N**, Guillemin GJ (2012). Neuroprotective effect of natural products against Alzheimer's disease. *Neurochem Res* 37:1829-1842 [Q2; IF: 2.551; Cited 28]
83. **Braidy N**, Jayasena T, Poljak A, Sachdev P (2012). Sirtuins in cognitive ageing and Alzheimer's disease. *Curr Opin Psychiatry* 25(3):226-30. [Q1; IF: 3.551; Cited 14]
84. Massudi H, Grant R, Guillemin G, **Braidy N** (2012). NAD⁺ Metabolism and Oxidative Stress: The Golden Nucleotide on a Crown of Thorns. *Redox Rep* 17:28-46 [Q2; IF: 1.71; Cited 13]
85. **Braidy N**, Muñoz P, Palacios A, Castellano-Gonzalez G, Inestrosa N, Chung R, Sachdev P, Guillemin G (2012). Recent rodent models for Alzheimer's Disease: Clinical implications and basic research. *J Neural Transm* 119:173–195 [Q2; IF: 2.871; Cited 25]
86. Massudi H, Grant R, **Braidy N**, Guest J, Farnsworth B, Guillemin GJ (2012). Age-associated changes in oxidative stress and NAD⁺ metabolism in human tissue. *PLoS One*. 7:e42357 [Q1; IF: 3.530; Cited 43]
87. Yeung YT, Bryce NS, Adams S, **Braidy N**, Konayagi M, McDonald KL, Teo C, Guillemin GJ, Grewal T, Munoz L (2012). p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. *J Neurooncol* 109:35-44 [Q2; IF: 2.787; Cited 14]

2011

88. **Braidy N**, Guillemin G, Mansour H, Chan-Ling T, Grant R (2011). Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats. *FEBS J* 278:4425–4434. [Q1; IF: 3.986; Cited 8]
89. **Braidy N**, Guillemin G, Mansour H, Chan-Ling T, Poljak A, Grant R (2011). Age related changes in NAD⁺ metabolism, oxidative stress and Sirt1 Activity in Wistar Rats. *PLoS One*. 6:e19194. [Q1; IF: 3.530; Cited 91]
90. **Braidy N**, Guillemin G, Grant R (2011). Effects of Kynurenine Pathway inhibition on NAD⁺ metabolism and cell viability in human primary astrocytes and neurons. *IJTR* 4:29-37. [Q3; IF: n/a; Cited 0]
91. Essa M, **Braidy N**, Al-Sharbati M, Al-Farsi Y, Ali A, Waly M, Al-Shaffae M, Guillemin G (2011). Elevated plasma leptin levels in autistic children of Sultanate of Oman. *Int J Biol Med Res* 2:803-805. [Q3; IF: n/a; Cited 32]
92. **Braidy N**, Bui K, Bajorek B. (2011). Evaluating the impact of new anticoagulants in the hospital setting. *Pharmacy Practice*. 9(1): 1-10. [Q2; IF: n/a; Cited 1]

2010

93. **Braidy N**, Grant R, Adams S, Guillemin G. (2010). Neuroprotective effects of naturally occurring polyphenols on quinolinic acid induced neurotoxicity in human neurons. *FEBS Journal*. 277: 368-382. [Q1; IF: 3.986; Cited 30]

2009

94. Rahman A, Ting K, Cullen K, **Braidy N**, Brew BJ, Guillemin GJ (2009). The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. *PLoS One*. 4(7): e6344. [Q1; IF: 3.530; Cited 51]
95. **Braidy N**, Grant R, Adams S, Guillemin G (2009). Mechanism for Quinolinic acid cytotoxicity in human astrocytes and neurons. *Neurotox Res*. 16: 77-86. [Q1; IF: 3.151; Cited 56]
96. **Braidy N**, Grant R, Brew BJ, Adams S, Jayasena T, Guillemin G (2009). Effects of Kynurenine Pathway Metabolites on Intracellular NAD⁺ Synthesis and Cell Death in Human Primary Astrocytes and Neurons. *IJTR* 2: 61-69. [Q3; IF: n/a; Cited 26]

2008

97. **Braidy N**, Guillemin G, Grant R. (2008). Promotion of cellular NAD⁺ anabolism: Therapeutic potential for Alzheimer's Disease and Aging. *Neurotox Res*. 13: 173-184. [Q1; IF: 3.151; Cited 25]

Book Chapters:

1. **Braidy N**, Poljak A, Jayasena T, Sachdev P (2017). Natural Plant-derived Acetylcholinesterase Inhibitors: Relevance for Alzheimer's disease. In Andrade, Valentao, Pereira (eds.) Natural Products Targeting Clinically-relevant Enzymes, Wiley-VCH Verlag [In Press].
2. **Braidy N**, Poljak A, Jayasena T, Sachdev P (2013). Ionotropic Receptors in the Central Nervous System and Neurodegenerative Disease. In Guillemin GJ (eds.) Handbook for Excitotoxicity, Springer, ISBN 978-1-4614-5835-7, p 1072-1092.
3. **Braidy N**, Poljak A, Jayasena T, Sachdev P (2013). Drug Treatments for Alzheimer's Disease: Hopes and Challenges. In Guillemin GJ (eds.) Handbook for Excitotoxicity, Springer, ISBN 978-1-4614-5835-7, p 1173-1190.
4. **Braidy N**, Poljak A, Jayasena T, Adams S, Sachdev P (2013). Glutamate in the Pathogenesis of Gliomas. In Guillemin GJ (eds.) Handbook for Excitotoxicity, Springer, ISBN 978-1-4614-5835-7, p 1287-1298.
5. Essa MM, **Braidy N**, Subash S, Vijayan RK, Guillemin GJ (2013). Excitotoxicity in the Pathogenesis of Autism. In Guillemin GJ (eds.) Handbook for Excitotoxicity, Springer, ISBN 978-1-4614-5835-7, p 1267-1271.
6. Marcal H, Wanandy N, Castellano-Gonzalez G, **Braidy N**, Guillemin GJ (2012). Curcumin: Medicinal Properties, Molecular Targets, and Biological Mechanisms. In Sasaki J and Kichida M (eds.) Curcumin: Biosynthesis, Medicinal Uses and Health Benefits. Nova Publishers 2012 2nd Quarter. ISBN: 978-1-61942-487-6, p 133-154.

Books:

1. **Braidy N** (2014). NAD⁺ Metabolism in Neurodegeneration and Ageing. Lambert Academic Press, Saarbrücken, Germany, ISBN 978-3-659-51773-0.
2. **Braidy N** (2014). Pomegranates: Old age remedy for today's diseases. Nova Publishers, Hauppauge, NY, USA, ISBN 978-1-63463-456-4.